Leveraging nearly 40 years of professional excellence, Dr. Michael S. Louie is well-regarded for his expertise in digital information for the life sciences industry and his longstanding tenure in chemistry. From 2022 to 2024, he was the senior vice president of digital transformation and chief information officer at Kodiak Sciences, where he contributed his knowledge to enhancing business processes through automation and digital transformation. Among his myriad of responsibilities, Dr. Louie was tasked with assessing business processes to identify opportunities for improvements in efficiency. To this end, he is proficient in implementing software tools to facilitate information management and drug development.
Earlier in his career, Dr. Louie served with Gilead Sciences for 29 years, culminating in his role as the vice president of analytical operations and information systems, serving in this capacity between 2019 and 2022. Previously, he was the vice president of information technology from 2016 to 2019, the senior director of information technology from 2010 to 2016, and the director of IT quality, security and compliance from 2006 to 2010. Likewise, he served tenures as the associate director of information technology between 1998 and 2006 and as a research scientist between 1993 and 1998. Other vocational appointments to Dr. Louie’s credit also include positions as a scientist at Monsanto from 1992 to 1993, an analytical chemist at the Syntex Corporation from 1986 to 1987, and an organic chemist at the Shell Agricultural Biological Sciences Research Center from 1985 to 1986.
Among his numerous career milestones, Dr. Louie is particularly proud of integrating technologies and managing data to improve data integrity, efficiency and traceability in pharmaceutical laboratories, which have all been crucial for drug manufacturing and quality control to ultimately ensure patient safety. Demonstrating his wealth of knowledge, Dr. Louie has presented at industry conferences and maintains affiliation with the American Chemical Society and the International Society for Pharmaceutical Engineering. He has also collaborated effectively with the Food and Drug Administration to develop artificial intelligence guidelines for machinery used in life sciences.
Recently, Dr. Louie has taken on advisory roles at high-tech companies in the life sciences industry. His focus is on leveraging artificial intelligence, machine learning, and neural networks to enhance business efficiency, improve product quality, and discover breakthroughs in disease diagnosis and personalized treatment. He envisions establishing an AI platform enabled by digital biomarkers derived from biometric imaging and other non-invasive diagnostic approaches. This platform could reveal significant new insights into neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Lewy body-related disorders. Additionally, it could improve the diagnosis and treatment of conditions related to diabetes, the retina, liver, and cardiovascular systems.
Contact Dr. Louie: